Innate Pharma Partners With Sobi To Advance Lacutamab Toward Phase 3, Targets Accelerated Approval Filing In Sézary Syndrome
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndromeMarkus Jensen appointed Chief Medical Officer, bringing
Innate Pharma teamed up with another company to test a new medicine for a rare skin disease and is moving toward asking the government for faster approval. When a company partners with others and moves toward approval, it often means they believe the medicine might work, which is worth watching.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.